Rafael Amado, Allogene head of R&D
October 6, 2022 04:02 PM EDTUpdated October 7, 03:40 PM
R&D

Af­ter call­ing a lengthy time out on the de­vel­op­ment field, Al­lo­gene fi­nal­ly kicks off a land­mark PhII piv­otal

John Carroll

Editor & Founder

When I talked with Al­lo­gene $AL­LO CEO David Chang back in the spring of 2020 about some new da­ta for their off-the-shelf CAR-T, he ea­ger­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

FDA lifts hold on En­trada's Duchenne drug af­ter two years

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times